ClinConnect ClinConnect Logo
Search / Trial NCT00785330

Trial Information

Current as of May 01, 2025

Completed

Keywords

Rituximab Non Hodgkin's Lymphoma Diffuse Large B Cell Lymphoma Peripheral T Cell Lymphoma Graft Versus Host Disease Graft Versus Lymphoma Effect Allogeneic Haematopoietic Stem Cell Transplantation Relapsed Or Primary Progressive Aggressive Non Hodgkin's Lymphoma

ClinConnect Summary

Patients in the age of 18 to 65 years with a high- risk relapse of a histology proven aggressive Non-Hodgkin's-lymphoma are eligible for the trial. Aggressive Non-Hodgkin's lymphoma within this study is defined as:

B-NHL:

follicular lymphoma grade III° lymphoblastic (precursor) lymphoma diffuse large cell cell lymphoma any subtype and variant including primary mediastinal lymphoma mantle cell lymphoma, blastic variant

T-NHL:

precursor T cell lymphoma peripheral T cell lymphoma, any subtype and variant angioimmunoblastic lymphoma anaplastic large cell lymphoma, any subtype NK / T cell ly...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • histology proven aggressive non Hodgkin's lymphoma and
  • primary progressive disease or
  • early relapse after less than 12 month of remission duration and at least one risk factor according to the international prognostic index (IPI or
  • relapse or progression after high dose chemotherapy and autologous transplantation or
  • relapse or progression and lack of an autologous stem cell product.
  • Exclusion Criteria:
  • severe comorbidity or impaired organ function
  • hypersensitivity to used drugs
  • HIV positivity
  • active hepatitis
  • other active malignant disease

About Institut Fuer Anwendungsorientierte Forschung Und Klinische Studien Gmbh

Institut für Anwendungsorientierte Forschung und Klinische Studien GmbH is a leading research organization dedicated to advancing clinical research and applied science. With a strong focus on innovative methodologies and robust study designs, the institute collaborates with various stakeholders in the healthcare sector to facilitate the development and evaluation of new therapeutic interventions. By leveraging a multidisciplinary team of experts, the organization aims to enhance patient outcomes through rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its commitment to excellence and scientific integrity positions it as a trusted partner in the clinical research landscape.

Locations

Hamburg, , Germany

Heidelberg, Baden Würtenberg, Germany

Marburg, Hessen, Germany

Homburg, Saarland, Germany

Göttingen, , Germany

Münster, , Germany

Patients applied

0 patients applied

Trial Officials

Bertram Glass, Prof. MD.

Study Director

Asklepios Klinik St. Georg

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials